CardioVascular Dynamics Obtains License to Novel Angioplasty Technology.

IRVINE, Calif.--(BUSINESS WIRE)--April 10, 1996--CardioVascular Dynamics Inc. (CVD), a subsidiary of EndoSonics Corp. (NASDAQ:ESON) announced today that it has signed an agreement to license a new technology called Facilitated Force Angioplasty (FFA).

This technology was developed by Michael Stillabower, M.D.

FFA Technology uses a novel catheter design concept that provides for the "controlled incision" of atherosclerotic plaque. The catheter design provides a mechanical means controlling the "scoring" or "cutting" of atherosclerotic plaque so that conventional angioplasty can then be completed using either the same catheter, or if desired, a second catheter.

FFA Technology was developed and patented by Stillabower, a practicing interventional cardiologist associated with the Medical Center of Delaware. Under the Agreement with Stillabower, CVD has received exclusive, worldwide rights to Stillabower's current patent for FFA and all future improvements. CVD has agreed to finalize the development of this technology, complete human clinical investigation and obtain all necessary regulatory approvals on a worldwide basis.

Commenting on this Licensing Agreement, CVD Chairman and CEO Michael R. Henson said, "Stillabower is both an extremely busy interventional cardiologist and a very creative inventor. We are pleased that he has decided to work with CVD to commercialize FFA Technology. This technology can have a significant impact on the interventional treatment of atherosclerosis. It has applications for patients who are candidates for conventional PTCA, as well as patients who might be treated with newer modalities such as rotational atherectomy or vascular stents."

CVD develops and markets site-specific drug delivery catheters, combined angioplasty-drug delivery catheters and advanced therapeutic catheters.

CONTACT: CardioVascular Dynamics, Inc.

Heather Murray, 714/457-9546